Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute myeloid leukemia: therapeutic indications.
Burnett AK, Kell J, Rowntree C. Burnett AK, et al. Among authors: kell j. Curr Opin Hematol. 2000 Nov;7(6):333-8. doi: 10.1097/00062752-200011000-00002. Curr Opin Hematol. 2000. PMID: 11055504 Review.
Guidelines on the management of acute myeloid leukaemia in adults.
British Committee for Standards in Haematology; Milligan DW, Grimwade D, Cullis JO, Bond L, Swirsky D, Craddock C, Kell J, Homewood J, Campbell K, McGinley S, Wheatley K, Jackson G. British Committee for Standards in Haematology, et al. Among authors: kell j. Br J Haematol. 2006 Nov;135(4):450-74. doi: 10.1111/j.1365-2141.2006.06314.x. Epub 2006 Oct 10. Br J Haematol. 2006. PMID: 17054678 Free article. Review. No abstract available.
Tipifarnib in acute myeloid leukemia.
Burnett AK, Kell J. Burnett AK, et al. Among authors: kell j. Drugs Today (Barc). 2007 Nov;43(11):795-800. doi: 10.1358/dot.2007.43.11.1088617. Drugs Today (Barc). 2007. PMID: 18174965
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. Burnett AK, et al. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8. Br J Haematol. 2009. PMID: 19291085 Free article. Clinical Trial.
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
Schiller GJ, O'Brien SM, Pigneux A, Deangelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ. Schiller GJ, et al. Among authors: kell j. J Clin Oncol. 2010 Feb 10;28(5):815-21. doi: 10.1200/JCO.2009.24.2008. Epub 2009 Dec 21. J Clin Oncol. 2010. PMID: 20026800 Clinical Trial.
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S, Yin J, Culligan D, Johnston P, Murphy J, McMullin MF, Hunter A, Das-Gupta E, Clark R, Carr R, Hills RK. Burnett AK, et al. Among authors: kell j. J Clin Oncol. 2010 May 10;28(14):2389-95. doi: 10.1200/JCO.2009.26.4242. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385984 Clinical Trial.
74 results